- Stocks
- Pharma & Healthcare
- Entero Healthcare Solutions
Entero Healthcare Solutions share price
NSE: ENTEROPharma & HealthcareMedical Distribution
Entero Healthcare Solutions at a glance
Entero Healthcare Solutions (NSE: ENTERO) closed at ₹1,504.20 on 22 Oct 2026, down 0.19% on the day. With a market capitalisation of ₹6,547 Cr, it ranks 689th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Distribution.
At its last close the stock traded at 57.1× trailing earnings, against a return on equity of 6.8% in FY26. Over the past year the share price has risen 36.0%. Its 52-week range is ₹944.00 (29 Dec 2025) to ₹1,920.00 (7 Sep 2026); the last close is 21.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹1,910 Cr (+42.6% year on year) and net profit ₹45 Cr (+43.6%), on a consolidated basis. Promoters held 52.40% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹6,547 CrRank 689 on NSE
- P/E (trailing)
- 57.1×
- Price to book
- 3.21×FY26
- EPS (TTM)
- ₹26.44to Q4 FY26
- ROE
- 6.8%FY26
- ROCE
- 12.0%FY26
- Debt to equity
- 0.34FY26
- Net profit margin
- 2.2%FY26
- Book value / share
- ₹388.09FY26
- 52-week high
- ₹1,920.007 Sep 2026
- 52-week low
- ₹944.0029 Dec 2025
- 1-year return
- +36.0%
- RSI (14-day)
- 32.5
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.19% | −5.7% | −16.4% | +21.2% | +36.0% |
Entero Healthcare Solutions quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,097 Cr | ₹1,301 Cr | ₹1,359 Cr | ₹1,339 Cr | ₹1,404 Cr | ₹1,571 Cr | ₹1,707 Cr | ₹1,910 Cr |
| Revenue YoY | +22.0% | +30.6% | +36.9% | +29.5% | +28.0% | +20.8% | +25.6% | +42.6% |
| Net profit | ₹21 Cr | ₹26 Cr | ₹29 Cr | ₹31 Cr | ₹30 Cr | ₹37 Cr | ₹34 Cr | ₹45 Cr |
| Net profit YoY | +219.3% | +399.6% | +321.9% | +48.3% | +47.2% | +40.6% | +15.0% | +43.6% |
| Net margin | 1.9% | 2.0% | 2.2% | 2.3% | 2.2% | 2.3% | 2.0% | 2.4% |
| EPS | ₹4.62 | ₹5.43 | ₹5.85 | ₹5.91 | ₹6.39 | ₹7.26 | ₹6.35 | ₹6.44 |
Entero Healthcare Solutions financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,780 Cr | ₹2,522 Cr | ₹3,300 Cr | ₹3,922 Cr | ₹5,096 Cr | — |
| Operating profit | −₹11 Cr | −₹20 Cr | −₹4 Cr | ₹36 Cr | ₹139 Cr | — |
| Net profit | −₹15 Cr | −₹29 Cr | −₹11 Cr | ₹40 Cr | ₹107 Cr | — |
| EPS (₹) | −₹5.00 | −₹9.00 | −₹3.00 | ₹11.00 | ₹22.00 | — |
| Cash from operations | −₹69 Cr | −₹35 Cr | −₹45 Cr | −₹37 Cr | −₹77 Cr | — |
| Total debt | ₹0 Cr | ₹37 Cr | ₹31 Cr | ₹46 Cr | ₹0 Cr | ₹123 Cr |
| Shareholders' equity | −₹32 Cr | −₹58 Cr | −₹69 Cr | ₹1,638 Cr | ₹1,724 Cr | ₹1,689 Cr |
Entero Healthcare Solutions shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 52.42% | 52.42% | 52.42% | 52.42% | 52.42% | 52.40% |
| Foreign institutions | 19.92% | 17.20% | 14.67% | 5.14% | 4.03% | 4.37% |
| Domestic institutions | 9.64% | 10.18% | 9.65% | 16.42% | 16.62% | 15.48% |
| Non-institutions | 18.02% | 20.19% | 23.26% | 26.02% | 26.93% | 27.75% |
Entero Healthcare Solutions vs peers
The listed Pharma & Healthcare companies nearest to Entero Healthcare Solutions by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MOREPENLABMorepen Laboratories | ₹125.70 | +5.63% | +141.6% | ₹6,888 Cr | 72.7 | — |
| SUPRIYASupriya Lifescience | ₹848.80 | −0.02% | +19.4% | ₹6,831 Cr | 32.7 | — |
| BLISSGVSBliss GVS Pharma | ₹638.00 | +2.42% | +319.4% | ₹6,766 Cr | 53.1 | — |
| SANOFISanofi India | ₹2,845.00 | +0.53% | −40.0% | ₹6,552 Cr | 21.2 | — |
| ENTEROEntero Healthcare Solutions | ₹1,504.20 | −0.19% | +36.0% | ₹6,547 Cr | 57.1 | — |
| KOVAIKovai Medical Center & Hospital | ₹5,738.00 | −2.24% | +190.4% | ₹6,279 Cr | 25.7 | — |
| NEPHROPLUSNephrocare Health Services | ₹599.90 | −0.84% | — | ₹6,019 Cr | 74.1 | — |
Ask anything about Entero Healthcare Solutions
Pivot answers on the live chart with evidence you can check, and tests strategies against ENTERO's own history. Try: “Why has ENTERO moved over the last three months?” · “Backtest a 50-day moving-average crossover on ENTERO over five years” · “Compare ENTERO with MOREPENLAB on margins and valuation”
Frequently asked questions about Entero Healthcare Solutions
What is the share price of Entero Healthcare Solutions today?
Entero Healthcare Solutions (NSE: ENTERO) last closed at ₹1,504.20 on 22 Oct 2026. Its 52-week high is ₹1,920.00 and its 52-week low is ₹944.00.
What is the market cap of Entero Healthcare Solutions?
Entero Healthcare Solutions' market capitalisation is ₹6,547 Cr (₹6,547 Cr) at the 22 Oct 2026 close, ranking 689th among the NSE companies Pivot tracks.
What is the P/E ratio of Entero Healthcare Solutions?
Entero Healthcare Solutions trades at a trailing P/E of 57.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 53.1.
What is the ROE and ROCE of Entero Healthcare Solutions?
Return on equity was 6.8% in FY26 and return on capital employed was 12.0% in FY26 (consolidated figures).
Is Entero Healthcare Solutions a debt-free company?
No. Entero Healthcare Solutions' debt-to-equity ratio was 0.34 in FY26, with total debt of ₹123 Cr.
What were Entero Healthcare Solutions' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Entero Healthcare Solutions reported revenue of ₹1,910 Cr, +42.6% year on year, and net profit of ₹45 Cr, +43.6% year on year.
How has Entero Healthcare Solutions stock performed over the last year?
Entero Healthcare Solutions' share price has risen 36.0% over the past year, +21.2% over three months and −16.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Entero Healthcare Solutions?
As of 30 Jun 2026: promoters 52.40%, foreign institutions 4.37%, domestic institutions 15.48%, non-institutions 27.75%.
Who are Entero Healthcare Solutions' competitors?
The listed Pharma & Healthcare companies closest to Entero Healthcare Solutions by market cap are Morepen Laboratories, Supriya Lifescience, Bliss GVS Pharma, Sanofi India, Kovai Medical Center & Hospital and Nephrocare Health Services.
Is Entero Healthcare Solutions a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Entero Healthcare Solutions' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ENTERO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with E · all NSE stocks · this page as text